Insilico Medicine

Insilico Medicine has a range of AI-powered tools to overhaul the drug discovery and development process. Artificial intelligence and multi-omics data help the company speed up the search for new targets, create new molecules and predict the success of clinical trials.

The platform can be used for different aspects of pharmaceutical research and development, including target identification, molecule design and clinical trial outcome prediction. Among its features:

• Target Identification: AI-based hypothesis generation and evaluation of gene targets for diseases.
• Molecule Design: Automated de-novo design and engineering of novel molecules with desired properties.
• Clinical Trial Prediction: Prediction of clinical trial success rates and identification of potential weaknesses in trial design.

Insilico Medicine's products include:

• PHARMA.AI: A comprehensive drug discovery software suite.
• PandaOmics: A platform for OMICs data analysis and visualization.
• Chemistry42: A full-featured small molecule drug discovery platform using generative AI and physics-based methods.
• inClinico: A platform for predicting clinical trial success rates and assessing risk.

Customers can use the tools to speed up drug discovery and reduce the time and expense of traditional methods. Insilico Medicine hopes to help people live longer, healthier lives by speeding up the development of drugs that help people. The platform is for pharmaceutical companies, researchers and clinicians looking to improve their pipeline.

Insilico Medicine has offices in Boston, New York, Montreal, Suzhou, Abu Dhabi, Shanghai, Taipei and Hong Kong, showing its global reach to support customers.

For more details, visit the Insilico Medicine website.

Published on July 22, 2024